Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MBRX – Moleculin Biotech Inc

Moleculin Biotech, Inc.
MBRX
$1.07
Name : Moleculin Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $15,116,426.00
EPSttm : -6.32
finviz dynamic chart for MBRX
Moleculin Biotech, Inc.
$1.07
0.93%
$0.01

Float Short %

5.18

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

1.04

EPS This/Next Y

0.43

Price

1.07

Target Price

10.67

Analyst Recom

1

Performance Q

110.84

Relative Volume

0.05

Beta

1.64

Ticker: MBRX




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-04-14MBRX0.82N/AN/A0
2025-04-15MBRX0.8175N/AN/A0
2025-04-16MBRX0.9178N/AN/A0
2025-04-17MBRX0.875N/AN/A0
2025-04-18MBRX0.8749N/AN/A0
2025-04-21MBRX0.95N/AN/A0
2025-04-22MBRX1.04N/AN/A0
2025-04-23MBRX1.0104N/AN/A0
2025-04-24MBRX1.09N/AN/A0
2025-04-25MBRX1.06N/AN/AN/A
2025-04-28MBRX0.9866N/AN/AN/A
2025-04-29MBRX1.01N/AN/A0
2025-04-30MBRX1.0607N/AN/A0
2025-05-01MBRX1.01N/AN/A0
2025-05-02MBRX1.04N/AN/A0
2025-05-05MBRX1.04N/AN/A0
2025-05-06MBRX1.01N/AN/A0
2025-05-07MBRX1.01N/AN/A0
2025-05-08MBRX0.9937N/AN/A0
2025-05-09MBRX1.055N/AN/A0
2025-05-12MBRX1.055N/AN/A0
2025-05-13MBRX1.055N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-04-14MBRX0.83- - -5.28
2025-04-15MBRX0.85- - -5.28
2025-04-16MBRX0.91- - -5.28
2025-04-17MBRX0.87- - -5.28
2025-04-18MBRX0.87- - -5.28
2025-04-21MBRX0.95- - -5.28
2025-04-22MBRX1.05- - -5.28
2025-04-23MBRX1.03- - -5.28
2025-04-24MBRX1.09- - -5.28
2025-04-25MBRX1.06- - -5.28
2025-04-28MBRX0.99- - -5.28
2025-04-29MBRX1.02- - -5.28
2025-04-30MBRX1.06- - -5.28
2025-05-01MBRX1.01- - -5.28
2025-05-02MBRX1.03- - -5.28
2025-05-05MBRX1.04- - -5.28
2025-05-06MBRX1.01- - -5.28
2025-05-07MBRX1.00- - -5.28
2025-05-08MBRX1.00- - -5.28
2025-05-09MBRX1.05- - -5.28
2025-05-12MBRX1.08- - -5.28
2025-05-13MBRX1.07- - -5.28
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-04-14MBRX0.003.224.08
2025-04-15MBRX0.003.224.08
2025-04-16MBRX0.003.224.08
2025-04-17MBRX0.003.224.08
2025-04-18MBRX0.003.224.08
2025-04-21MBRX0.001.014.08
2025-04-22MBRX0.001.014.08
2025-04-23MBRX0.001.014.08
2025-04-24MBRX0.001.014.08
2025-04-25MBRX0.001.014.08
2025-04-28MBRX0.001.013.32
2025-04-29MBRX0.001.013.32
2025-04-30MBRX0.001.013.32
2025-05-01MBRX0.001.013.32
2025-05-02MBRX0.001.013.32
2025-05-05MBRX0.001.023.32
2025-05-06MBRX0.001.023.32
2025-05-07MBRX0.001.023.32
2025-05-08MBRX0.001.023.32
2025-05-09MBRX0.001.023.32
2025-05-12MBRX0.001.095.18
2025-05-13MBRX0.001.095.18
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

1.09

Beta

1.64

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

5

Growth Score

21

Sentiment Score

47

Actual DrawDown %

99.2

Max Drawdown 5-Year %

-99.6

Target Price

10.67

P/E

Forward P/E

PEG

P/S

P/B

0.6

P/Free Cash Flow

EPS

-7.12

Average EPS Est. Cur. Y​

-5.28

EPS Next Y. (Est.)

-4.85

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.05

Return on Equity vs Sector %

-387.7

Return on Equity vs Industry %

-370.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Moleculin Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 17
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 3 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
stock quote shares MBRX – Moleculin Biotech Inc Stock Price stock today
news today MBRX – Moleculin Biotech Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MBRX – Moleculin Biotech Inc yahoo finance google finance
stock history MBRX – Moleculin Biotech Inc invest stock market
stock prices MBRX premarket after hours
ticker MBRX fair value insiders trading